A5066189149- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Neutropenia and Cancer Infections
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Hematological disorders and diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Blood disorders and treatments
- Immunotherapy and Immune Responses
- Cancer survivorship and care
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Intraoperative Neuromonitoring and Anesthetic Effects
- Gastric Cancer Management and Outcomes
- Family Support in Illness
- Bone health and treatments
- Metabolism, Diabetes, and Cancer
- Anesthesia and Pain Management
- BRCA gene mutations in cancer
- RNA Interference and Gene Delivery
- Bone health and osteoporosis research
- Nausea and vomiting management
Novartis (Italy)
2019-2022
Ospedale Policlinico San Martino
2022
Roche (Switzerland)
2021
Istituti di Ricovero e Cura a Carattere Scientifico
2008-2020
Policlinico San Matteo Fondazione
2007-2020
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2019
IRCCS Ospedale San Raffaele
2019
University of Pavia
2009-2017
ASST Fatebenefratelli Sacco
2017
Mario Negri Institute for Pharmacological Research
2017
Abstract Receptor activator of NFκB ligand (RANKL), RANK, and osteoprotegerin (OPG) represent the key regulators bone metabolism both in normal pathological conditions, including metastases. To our knowledge, no previous studies investigated compared RANK expression primary tumors metastases from same patient. We retrospectively examined by immunohistochemistry 74 tissues solid tumors, mostly breast, colorectal, renal, lung, prostate cancer. For 40 cases, tissue corresponding tumor was also...
Abstract Background. We evaluated the patterns of care and clinical outcomes metastatic breast cancer patients treated with first-line trastuzumab-based therapy after previous (neo)adjuvant trastuzumab. Materials Methods. A total 416 consecutive, HER2-positive who had received were identified at 14 Italian centers. 113 presented de novo stage IV disease analyzed separately. Dichotomous using logistic regression time-to-event Cox proportional hazards models. Results. In 202 trastuzumab-naïve...
Aims and background Palonosetron, a unique second-generation 5-HT3 receptor antagonist, has been demonstrated to control emesis related chemotherapy-induced nausea vomiting (CINV). The aim of this study was evaluate the efficacy tolerability palonosetron followed by single dose dexamethasone in patients with breast cancer (BC) or colorectal (CRC) receiving moderate emetogenic chemotherapy (MEC). Methods design Chemotherapy-naive BC CRC were given MEC as adjuvant first-line treatment....
Aims and background Palonosetron, a unique second-generation 5-HT3 receptor antagonist, has been demonstrated to control emesis related chemotherapy-induced nausea vomiting (CINV). The aim of this study was evaluate the efficacy tolerability palonosetron followed by single dose dexamethasone in patients with breast cancer (BC) or colorectal (CRC) receiving moderate emetogenic chemotherapy (MEC). Methods design Chemotherapy-naive BC CRC were given MEC as adjuvant first-line treatment....
The efficacy of high-dose chemotherapy (HDC) and autologous hemopoietic progenitor cell transplantation (AHPCT) for breast cancer (BC) patients has been an area intense controversy among the medical oncology community. aim this study was to assess toxicity procedure in a large cohort high-risk primary BC who underwent AHPCT Italy. A total 1183 receiving HDC (HRBC) (>3 positive nodes) were identified Italian registry. median age 46 years, 62% premenopausal at treatment, 60.1% had...
Pegfilgrastim is a covalent conjugate of filgrastim and polyethylene glycol that has proved to be effective in supporting myelopoiesis during chemotherapy. Since very limited information available on the biological effects pegfilgrastim neutrophils exposed chemotherapy, we analyzed following parameters patients undergoing dose-dense chemotherapy for breast cancer: apoptosis, by TUNEL technique; actin polymerization, using FITC-labeled phalloidin, alkaline phosphatase activity cytochemistry....
Abstract Background: The primary objective of this phase IIIb, single arm trial is to study circulating tumor DNA (ctDNA) alterations, their evolution during treatment and association with clinical outcome in patients receiving ribociclib letrozole as first-line therapy for aBC. Here we report baseline ctDNA mutational status its correlation clinical-pathological characteristics response on the basis first imaging evaluation. Methods: From February December 2018, 287 post-menopausal (pts)...
Ribociclib plus an aromatase inhibitor and ovarian function suppression is the preferred first-line option for pre-/perimenopausal women with hormone receptor-positive/human epidermal growth factor receptor-2-negative advanced or metastatic breast cancer. We opened italian managed access program (MAP) that permitted to ribociclib selected patients allowed collect informative results on clinical impact of therapy. The MAP (April 2018–May 2020) included 64 premenopausal patients,...
1012 Background: Independent early dynamic assessment (baseline [D0] and day 15 of first cycle [D15]) both TKa ctDNA was prognostic predictive in pts with HR+, HER2− ABC treated RIB+LET enrolled the BioItaLEE trial (NCT03439046). Here we performed a combined analysis these two biomarkers. Methods: 287 were study. Overall, dynamics assessable for biomarkers 241/287 (84.0%). Methods applied evaluation previously reported. For ctDNA, samples defined as wild type (WT) if no mutations observed at...
Sequential administration of the association 5-fluorouracil, epirubicin and cyclophosphamide (FEC) paclitaxel could be better tolerated than an anthracycline while having a similar antitumour effect. 69 patients with advanced breast cancer previously untreated anthracyclines or entered phase II multicentre study in which FEC was followed by paclitaxel. Both regimens were administered 4 times every 21 days. The median follow-up is 20 months 38/69 have died. Grade III–IV toxicity acceptable....
Breast cancer affects patients both emotionally and physically. It is time to consider distress as the sixth vital sign in breast Europe. Between 2012 2015, our EUSOMA-certified multi-disciplinary group conducted a study on emotional quality-of-life at diagnosis, observed their trend over first 8 months of treatment. One hundred forty-nine concluded program. The psycho-oncologist nurses gave out SF36, Hospital Anxiety Depression Scale Distress Thermometer. Our Italian data go along with...
Ribociclib plus letrozole demonstrated manageable safety and efficacy profiles in hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2−) advanced breast cancer (ABC) the Phase 3b CompLEEment-1 trial. To evaluate of ribociclib Italian subpopulation with HR+, HER2− ABC from Patients received (600 mg/day, 3 weeks on/1 week off) (2.5 mg/day) while men premenopausal women additionally goserelin. were allowed ≤ 1 line prior chemotherapy an Eastern Cooperative...
Sequential docetaxel and gemcitabine following initial plus epirubicin or vinorelbine association could be worthwhile as first-line treatment of metastatic breast cancer.Fifty-eight patients entered a phase II study that included two sequential phases. In the first phase, 36 22 previously unexposed exposed to adjuvant anthracyclines received (75 mg/m2, day 1) with (20 days 1 5), respectively, every 21 for 4 courses. second who had response (R) stable disease (SD) (35 mg/m2) (800 on 1, 8 15...
Pegfilgrastim is a covalent conjugate of filgrastim and polyethylene glycol with an increased elimination half-life due to decreased serum clearance. Few data are available on biological effects pegylated granulocyte colony-stimulating factor. At our center two clinical trials currently ongoing that will further evaluate pegfilgrastim utilized in dose-dense regimens for breast cancer patients both as neoadjuvant adjuvant approach. We analyzed some parameters peripheral neutrophils 17...
The addition of trastuzumab to chemotherapy for HER2-positive metastatic breast cancer has significantly improved progression-free survival and overall survival, although most patients develop resistance or have a primarily resistant disease. aim the study was describe efficacy safety first-line treatment in unselected patients, treated according clinical practice.From 2000 2009, we conducted retrospective multi-institutional analysis 182 consecutive with who underwent trastuzumab. primary...